Books+ Search Results
Prodrugs Challenges and Rewards
Title
Prodrugs [electronic resource] : Challenges and Rewards / edited by Valentino Stella, Ronald Borchardt, Michael Hageman, Reza Oliyai, Hans Maag, Jefferson Tilley.
ISBN
9780387497853
Edition
1st ed. 2007.
Publication
New York, NY : Springer New York : Imprint: Springer, 2007.
Physical Description
1 online resource (XVIII, 1,464 p).
Local Notes
Access is available to the Yale community.
Access and use
Access restricted by licensing agreement.
Summary
Prodrugs are substances administered in an inactive form that is then metabolized in the body in vivo into the active compound. The rationale behind administering prodrugs is to optimize absorption, distribution, metabolism, and excretion of these drugs. Since first described in the 1950s, prodrugs continue to be a fertile area of research. There are a number of small pharmaceutical/biotech companies dedicated to using prodrugs for the delivery of older but problematic drugs as well as to developing broad-based prodrug technologies for application to new and future drugs. These volumes represent a comprehensive guide to prodrugs and will guide the reader through the current status of the prodrug concept and its many applications and to highlight its many successes in overcoming formulation and delivery of problematic drugs.
Variant and related titles
Springer ENIN.
Other formats
Printed edition:
Printed edition:
Printed edition:
Format
Books / Online
Language
English
Added to Catalog
July 30, 2019
Series
Biotechnology: Pharmaceutical Aspects ; V
Contents
A Case for Prodrugs
A Case for Prodrugs
Problems Addressable by Prodrugs
Prodrug Approaches to Enhancing the Oral Delivery of Poorly Permeable Drugs
Topical Delivery Using Prodrugs
Prodrug approaches to ophthalmic drug delivery
Overcoming Poor Aqueous Solubility of Drugs for Oral Delivery
Prodrugs and Parenteral Drug Delivery
Poly (ethylene glycol) Prodrugs: Altered Pharmacokinetics and Pharmacodynamics
Prodrugs to Reduce Presystemic Metabolism
Controlled Release — Small Molecules
Controlled Release - Macromolecular Prodrugs
Controlled Release - Proenzymes
Targeting - Theoretical and Computational Models
Targeting - Cancer — Small Molecules
Monoclonal Antibody Drug Conjugates for Cancer Therapy
Antibody-Directed Enzyme Prodrug Therapy
Prodrugs for Liver-targeted Drug Delivery
Prodrug Approaches for Drug Delivery to the Brain
Lymphatic Absorption of Orally Administered Prodrugs
Colonic Delivery
Functional Group Approach to Prodrugs
Prodrugs of Carboxylic Acids
Prodrugs of Alcohols and Phenols
Prodrugs of Amines
Prodrugs of Amides, Imides and Other NH-acidic Compounds
Prodrugs of Benzamidines
Prodrugs of Phosphonates, Phosphinates, and Phosphates
Functional Group Approaches to Prodrugs: Functional Groups in Peptides
Macromolecular Prodrugs of Small Molecules
Miscellaneous Functional Groups
Prodrugs — Preclinical and Clinical Considerations
Prodrugs: Absorption, Distribution, Metabolism, Excretion (ADME) Issues
Formulation Challenges of Prodrugs
Safety Assessment of Prodrugs
Toxicological Issues with Pivalate Prodrugs
Case Studies
Case Study: Adefovir Dipivoxil: An Oral Prodrug of Adefovir
Case Study: Amifostine: (Ethyol®)
Case Study: Capecitabine: A Prodrug of 5-Fluorouracil
Case Study: Cefditoren Pivoxil: An Oral Prodrug of Cefditoren
Case Study: Cefuroxime Axetil: An Oral Prodrug of Cefuroxime
Case Study: Clindamycin 2-Phosphate, A Prodrug of Clindamycin
Case Study: Enalapril: A Prodrug of Enalaprilat
Case Study: Famciclovir: A Prodrug of Penciclovir
Case Study: Fosamprenavir: A Prodrug of Amprenavir
Case Study: Fosinopril
Case Study: Fosphenytoin: A Prodrug of Phenytoin
Case Study: Irinotecan (CPT-11), A Water-soluble Prodrug of SN-38
Case Study: Latanoprost: Isopropylester of a Prostaglandin F2? Analog
Case Study: Moexipril Hydrochloride: A Prodrug of Moexiprilat
Case Study: Mycophenolate Mofetil
Case Study: Olmesartan Medoxomil: A Prodrug of Olmesartan
Case Study: Omeprazole (Prilosec®)
Case Study: Oseltamivir: An Orally Bioavailable Ester Prodrug of Oseltamivir Carboxylate
Case Study: Parecoxib: A Prodrug of Valdecoxib
Case Study: Tenofovir Disoproxil Fumarate: An Oral Prodrug of Tenofovir
Case Study: Travoprost: A Potent PGF2? Analog
Case Study: Valacyclovir: A Prodrug of Acyclovir
Case Study: Valganciclovir: A Prodrug of Ganciclovir
Case Study: Vantin: A Prodrug of Cefpodoxime
Case Study: Ximelagatran: A Double Prodrug of Melagatran.
Subjects
Also listed under
SpringerLink (Online service)
Bookmark As
Citation
